Inactive Instrument

NEOVACS Stock Xetra

0LW

FR0004032746

Biotechnology & Medical Research

End-of-day quote Xetra Other stock markets
- ^EUR	-

11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

News in other languages: NEOVACS

15/06	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
22/05	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
22/05	L'IA reprend le leadership
04/05	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
04/05	Coup de théâtre ou coup d'épée dans l'eau ?

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-0.48%	+7.20%	-5.65%	+3.69%	46.2B
REVOLUTION MEDICINES, INC.	+2.19%	+11.71%	+393.31%	+609.31%	38.71B
IQVIA HOLDINGS INC.	+2.53%	+13.93%	+21.38%	-10.96%	31.9B
BEONE MEDICINES AG	+1.65%	+3.61%	+16.04%	+55.24%	31.12B
CELLTRION, INC.	-4.16%	-2.58%	+8.94%	+26.14%	23.77B
ASCENDIS PHARMA A/S	-0.32%	+12.96%	-	-	16.2B
MEDPACE HOLDINGS, INC.	+1.37%	+14.53%	+69.64%	+136.34%	15.05B
EUROFINS SCIENTIFIC SE	+1.00%	+10.30%	+13.31%	+23.36%	13.74B
IONIS PHARMACEUTICALS, INC.	+3.63%	+9.53%	+103.97%	+106.25%	13.42B
Average	+0.82%	+9.14%	+77.62%	+118.67%	25.57B
Weighted average by Cap.	+0.75%	+8.71%	+88.75%	+138.12%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	4.09K 4.66K 3.77K 3.53K 6.62K 440K 6.75K 45.3K 17.53K 217K 17.51K 17.13K 754K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -229K -185K -173K -325K -21.62M -332K -2.23M -862K -10.69M -861K -842K -37.06M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	0.01%	Yield 2023 *	-	Yield 2024	-

11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates
05/06/24	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

	2023	2024
Net sales	533K 608K 492K 460K 863K 57.39M 881K 5.91M 2.29M 28.36M 2.28M 2.23M 98.35M	434K 495K 400K 374K 702K 46.69M 717K 4.81M 1.86M 23.07M 1.86M 1.82M 80.01M
Net income	-8.74M -9.97M -8.06M -7.55M -14.15M -941M -14.44M -96.87M -37.48M -465M -37.44M -36.63M -1.61B	-32.91M -37.54M -30.34M -28.4M -53.26M -3.54B -54.37M -365M -141M -1.75B -141M -138M -6.07B
Net Debt	-237K -270K -218K -204K -383K -25.44M -391K -2.62M -1.01M -12.58M -1.01M -991K -43.61M	-205K -234K -189K -177K -332K -22.06M -339K -2.27M -879K -10.9M -878K -859K -37.81M

NEOVACS Stock Xetra

Stocks

0LW

FR0004032746

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile